DPT, or N,N-dipropyltryptamine, is a synthetic tryptamine with two propyl groups attached to the terminal nitrogen. It is structurally related to DMT and other simple dialkyltryptamines. DPT has been discussed in the context of experimental psychotherapy and has been studied in animal models, but human clinical evidence remains too limited for a modern safety assessment.
Chemistry and early use
DPT is N,N-dipropyl-2-(1H-indol-3-yl)ethanamine. It has an unsubstituted indole ring and two straight-chain propyl groups on the terminal nitrogen. The compound was synthesised in the 1950s and later appeared in scientific literature describing its use as an adjunct in psychotherapy, including historical work involving people with alcohol dependence.
DPT is chemically distinct from DiPT, which carries branched isopropyl groups, and DET, which has shorter ethyl substituents.
Pharmacology
Experimental research indicates that DPT interacts with serotonin receptors, particularly 5-HT2A and 5-HT1A. A 2008 study examined hallucinogen-like effects in rodents and found that the behavioural response was influenced by both receptor systems (Fantegrossi and colleagues, 2008).
Separate receptor-binding work reported partial agonist activity at the human 5-HT1A receptor. Other experiments found inhibition of serotonin reuptake in rat synaptosomes. Together, these results suggest a serotonergic mechanism, but the complete receptor profile is not as well mapped as that of several established psychedelic compounds (Thiagaraj and colleagues, 2005).
Reported effects and historical clinical context
Older descriptions and user reports refer to changes in visual perception, emotional state and sensory processing. Historical psychotherapy literature is sometimes cited as evidence of human exposure, but those reports were not modern controlled clinical trials. They do not establish efficacy for a psychiatric or substance-use disorder.
The literature offers no reliable estimate of how often particular effects or adverse reactions occur. Descriptions of DMT, DET or DiPT should not be substituted for compound-specific evidence about DPT.
Clinical and toxicological evidence
There is little published clinical toxicology specific to DPT. A 2020 review of tryptamine-related intoxications noted that DPT was rarely encountered in toxicology cases and that published human toxicity reports were scarce (Toxicology and Analysis of Psychoactive Tryptamines, 2020).
The lack of a large case series does not establish safety. Human pharmacokinetics, acute toxic range, dependence potential and long-term effects remain poorly characterised.
Research limitations
DPT has a longer history in experimental and historical literature than many newer tryptamines, but the evidence is fragmented. Animal receptor studies, older psychotherapy reports and anecdotal accounts answer different questions and should not be combined into a single, definitive clinical profile.
Related tryptamines
DPT is related to DMT, DET, DiPT and EPT. Its N,N-dipropyl side chain distinguishes it from the diethyl and diisopropyl analogues.
